	US 7,572,448 B2
	Combined cancer treatment methods using selected antibodies to aminophospholipids
Philip E. Thorpe, Dallas, Tex. (US); Xianming Huang, Dallas, Tex. (US); and Sophia Ran, Riverton, Ill. (US)
Assigned to Board of Regents, The University of Texas System, Austin, Tex. (US)
Filed on Aug. 15, 2003, as Appl. No. 10/642,058.
Application 10/642058 is a continuation in part of application No. 10/621269, filed on Jul. 15, 2003.
Claims priority of provisional application 60/396263, filed on Jul. 15, 2002.
Prior Publication US 2005/0031620 A1, Feb. 10, 2005
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01)

U.S. Cl. 424—155.1 [424/130.1; 424/141.1; 424/174.1]

73 Claims

1. A method for treating an animal with cancer, comprising administering to said animal a therapeutically effective amount of a first anti-cancer agent; and further comprising:

(a) subjecting said animal to surgery or radiotherapy; or

(b) administering to said animal a therapeutically effective amount of at least a second anti-cancer agent;

wherein said first anti-cancer agent is a purified antibody, or antigen-binding fragment thereof, that comprises at least two variable regions that each comprises three CDRs, wherein said two variable regions are:

(i) a heavy chain variable region that comprises variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VH CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12; and

(ii) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VL CDR1 has the amino acid sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.